Skip Navigation



NDT Advance Access published online on June 20, 2008
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfn328
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/10/3365    most recent
gfn328v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Campbell, N.
Right arrow Articles by Almond, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Campbell, N.
Right arrow Articles by Almond, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Update on reintroduction of epoetin in a patient with pure red call aplasia

Correspondence and offprint requests to: E-mail: docnjc@yahoo.com

The first 10% of the full text of this article appears below.

Sir,

A recent review of recombinant human erythropoietin (rHuEPO)-associated pure red cell aplasia (PRCA) cautioned re-challenge with the same or alternative rHuEPO products in the face of continued . . . [Full Text of this Article]

Neil Campbell, Sarietha Krishnakumar, Ante Matijevic and Mike Almond

Department of Renal Medicine Southend University Hospital NHS Trust, Westcliff-on-Sea, UK


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?